CAN508

Item no.	HY-100429-1mg
Manufacturer	MedChem Express
CASRN	140651-18-9
Amount	1 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.59
Formula	C9H10N6O
Citations	[1]Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.<br>[2]Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710.
Smiles	OC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Product Description	CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].
StorageTemperature	4°C (Powder, protect from light)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	218.22
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 250 mg/mL (ultrasonic)
Manufacturers Target	CDK
Isoform	CDK1; CDK2; CDK4; CDK7; CDK9
Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Request delivery time